THE 2-MINUTE RULE FOR ABBV-744 IN THE TREATMENT OF DRUG-RESISTANT CANCERS

In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will acquire treatment until finally disease progression or maybe the contributors are not able to tolerate the study drugs.For all circulation cytometry experiments, ten,000 cells for each replicate were an